Cellebrite DI 過去の業績
過去 基準チェック /36
Cellebrite DIの収益は年間平均-26.5%の割合で減少していますが、 Software業界の収益は年間 増加しています。収益は年間30.7% 17.1%割合で 増加しています。 Cellebrite DIの自己資本利益率は10.9%であり、純利益率は11.3%です。
主要情報
-26.52%
収益成長率
-30.58%
EPS成長率
| Software 業界の成長 | 17.33% |
| 収益成長率 | 17.09% |
| 株主資本利益率 | 10.92% |
| ネット・マージン | 11.33% |
| 前回の決算情報 | 30 Jun 2026 |
最近の業績更新
Recent updates
ナラティブ更新 • Sep 03
CLBT: AI Evidence Platform And Cloud Risks Will Shape Future Earnings Power
Analysts have trimmed the Cellebrite DI fair value estimate to $12.50 from $15.00. This reflects updated views on slower revenue growth, slightly lower discount rates, improved profit margin assumptions, and a reset in future P/E expectations following reduced revenue guidance and longer sales cycles cited in recent research.Seeking Alpha • Sep 02
Cellebrite: Mobile Forensics Leadership At A Compelling Valuation
Summary Cellebrite offers ~90% recurring revenue and 117% net retention, anchored by mobile forensics leadership and new growth levers. Cellebrite is rated 'Buy' at ~$12, with a Fair Value estimate of $17.3, reflecting ~44% potential upside and a strong GARP profile. I see a narrow moat based on their leadership in mobile forensics, robust rule of X score, and cross-selling opportunities. Risks include quantum disruption, geopolitical exposure in Israel, and device maker advances; conservative scenarios suggest the current valuation is fair. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 14
CLBT: Federal AI And Cloud Demand Will Support Premium Future P/E Potential
Cellebrite DI's analyst price target has shifted lower from about $21 to roughly $15, as analysts factor in the new CEO appointment, reduced 2026 revenue guidance, softer ARR trends, and longer sales cycles highlighted in recent research updates. Analyst Commentary Recent research on Cellebrite DI highlights a mixed setup.分析記事 • Jun 20
Cellebrite DI (CLBT) Stock Could Be 23% Undervalued After Genesis AI Launch
Cellebrite DI (NasdaqGS:CLBT) is drawing fresh attention after announcing general availability of Cellebrite Genesis, an AI-driven digital evidence tool that early law enforcement users report is reshaping how complex investigations are handled. See our latest analysis for Cellebrite DI. The Cellebrite DI share price has pulled back in recent months, with a 90 day share price return of 10.09% and a year to date share price return of 28.08% in the red. However, the 3 year total shareholder...ナラティブ更新 • Jun 19
CLBT: AI Evidence Platform And Cloud Authorizations Will Shape Earnings Power
Analysts have adjusted the Cellebrite DI price target from $18 to $15, citing updated views on valuation multiples, while still highlighting a large and growing addressable market and multiple drivers for recurring revenue growth. Analyst Commentary on Cellebrite DI Recent research on Cellebrite DI reflects a mix of optimism about the company's addressable market and recurring revenue potential, alongside a more cautious stance on valuation.ナラティブ更新 • Jun 04
CLBT: Federal AI And Cloud Adoption Will Support Premium P/E Potential
Analysts have nudged the fair value estimate for Cellebrite DI slightly lower from $21.67 to $21.00, tying this adjustment to modestly revised assumptions for revenue growth, profit margins, and future P/E multiples, following recent research that highlights both multiple compression and a large, growing addressable market. Analyst Commentary Recent research highlights a mix of optimism and caution on Cellebrite DI, with views anchored in the size of the opportunity, the pace of recurring revenue growth, and the impact of multiple compression on valuation.ナラティブ更新 • May 19
CLBT: Multiple Compression And Cloud Wins Will Shape Medium Term Earnings Power
Cellebrite DI’s analyst price target has been revised from $23 to $15, as analysts factor in multiple compression alongside updated assumptions for the discount rate, revenue growth, profit margin, and forward P/E. Analyst Commentary Bearish analysts have trimmed price targets on Cellebrite DI, highlighting concerns that the stock’s prior valuation left limited room for error even as quarterly results compared well with consensus expectations.ナラティブ更新 • Apr 22
CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential
Analysts have trimmed their price targets on Cellebrite DI by $2. This reflects updated views on the stock's risk profile and valuation assumptions, while core growth and margin expectations remain largely unchanged.ナラティブ更新 • Apr 07
CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential
Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event.ナラティブ更新 • Mar 24
CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential
Analysts trimmed their price targets for Cellebrite DI by $2 to $21.67, citing updated assumptions on discount rate, long term revenue growth, profit margin and future P/E. These changes keep fair value broadly unchanged while slightly adjusting the risk and return profile.ナラティブ更新 • Mar 09
CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration
Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged. Analyst Commentary Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions.ナラティブ更新 • Feb 23
CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power
Analysts have adjusted their average price target on Cellebrite DI to about $21.67, down from the previous $24.71 level. The revised target reflects updated views on fair value, profit margins and future P/E assumptions following recent research updates from multiple firms.ナラティブ更新 • Feb 08
CLBT: Higher Profitability Assumptions Will Support Stronger Medium Term Earnings Power
Analysts have raised their price target on Cellebrite DI from US$18.00 to US$23.00, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E as the key drivers of the change. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, with expected revenue between US$123 million and US$128 million and annual growth guidance of 13% to 17% (company guidance).ナラティブ更新 • Jan 25
CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power
Analysts have maintained their price target on Cellebrite DI at US$24.71, with only minor tweaks to inputs such as the discount rate and forward P/E, reflecting stable expectations around revenue growth and profit margin assumptions. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, targeting revenue of US$123 million to US$128 million, with annual growth of 13% to 17% (company guidance).分析記事 • Jan 13
Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit
With a price-to-sales (or "P/S") ratio of 9.7x Cellebrite DI Ltd. ( NASDAQ:CLBT ) may be sending very bearish signals...ナラティブ更新 • Jan 10
CLBT: Sustained Margin Strength Will Support Future Earnings Power
Analysts have maintained their fair value estimate for Cellebrite DI at US$24.71, making only minor adjustments to inputs such as the discount rate and long term P/E assumptions. This reflects a view that recent information does not materially alter their price outlook.ナラティブ更新 • Dec 24
CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead
Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, citing incremental improvements in the company’s discount rate assumptions and sustained expectations for high revenue growth and robust profit margins. What's in the News Cellebrite DI issued fourth quarter 2025 revenue guidance of $123 million to $128 million, implying year over year growth of 13% to 17% (company guidance).ナラティブ更新 • Dec 10
CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead
Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).ナラティブ更新 • Nov 26
CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year
Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.ナラティブ更新 • Sep 23
Cloud SaaS Solutions Will Drive Digital Forensics Adoption
Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.分析記事 • Sep 09
What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You
Cellebrite DI Ltd. ( NASDAQ:CLBT ) shareholders would be excited to see that the share price has had a great month...分析記事 • Aug 18
Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
NasdaqGS:CLBT 1 Year Share Price vs Fair Value Explore Cellebrite DI's Fair Values from the Community and select yours...ナラティブ更新 • Aug 15
Cloud SaaS Solutions Will Drive Digital Forensics Adoption
Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.収支内訳
収支内訳
Cellebrite DI の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 26 | 514 | 58 | 241 | 130 |
| 31 Mar 26 | 496 | 71 | 231 | 122 |
| 31 Dec 25 | 476 | 78 | 220 | 114 |
| 30 Sep 25 | 456 | 76 | 212 | 110 |
| 30 Jun 25 | 437 | -151 | 199 | 107 |
| 31 Mar 25 | 419 | -194 | 190 | 102 |
| 31 Dec 24 | 401 | -283 | 183 | 98 |
| 30 Sep 24 | 385 | -317 | 175 | 95 |
| 30 Jun 24 | 362 | -103 | 166 | 89 |
| 31 Mar 24 | 343 | -112 | 161 | 86 |
| 31 Dec 23 | 325 | -81 | 154 | 84 |
| 30 Sep 23 | 306 | -64 | 145 | 82 |
| 30 Jun 23 | 294 | -42 | 145 | 84 |
| 31 Mar 23 | 280 | 20 | 142 | 82 |
| 31 Dec 22 | 271 | 116 | 138 | 81 |
| 30 Sep 22 | 265 | 165 | 138 | 80 |
| 30 Jun 22 | 259 | 152 | 142 | 75 |
| 31 Mar 22 | 255 | 122 | 132 | 70 |
| 31 Dec 21 | 246 | 70 | 124 | 66 |
| 30 Sep 21 | 236 | 7 | 118 | 61 |
| 30 Jun 21 | 223 | 7 | 98 | 58 |
| 31 Mar 21 | 209 | 2 | 96 | 56 |
| 31 Dec 20 | 195 | -9 | 92 | 54 |
| 31 Dec 19 | 172 | -10 | 91 | 47 |
質の高い収益: CLBTは 高品質の収益 を持っています。
利益率の向上: CLBT過去に利益を上げました。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: CLBT過去 5 年間で収益を上げており、収益は年間-26.5%増加しています。
成長の加速: CLBTは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。
収益対業界: CLBT昨年収益を上げたため、昨年の収益成長をSoftware業界 ( 27.2% ) と比較することは困難です。
株主資本利益率
高いROE: CLBTの 自己資本利益率 ( 10.9% ) は 低い とみなされます。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 06:03 |
| 終値 | 2026/09/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cellebrite DI Ltd. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Tyler Radke | Citigroup Inc |
| Jeffrey Van Rhee | Craig-Hallum Capital Group LLC |
| Rudy Kessinger | D.A. Davidson & Co. |